Major pharmaceutical companies continually research and develop new cancer drugs and treatments, which must be shown to be safe and effective before doctors can prescribe them to patients. Through lymphoma clinical trials, researchers test the effects of new medications on a group of volunteers with lymphoma. Following a strict protocol and using carefully controlled conditions, researchers evaluate the drugs under development and measure the ability of the new drug to treat lymphoma, its safety, and any possible side effects.
Some patients with lymphoma are reluctant to take part in clinical trials for fear of getting no treatment at all for their lymphoma. This is simply not true. Patients with lymphoma who participate in lymphoma clinical trials receive the most effective therapy currently available for their condition -- or they may receive lymphoma treatments that are being evaluated for future use. These lymphoma treatments may be even more effective than currently available lymphoma treatments. The only way to determine if the newer treatment is better than currently available treatments is by clinical trial participation.
Note: Some citations in the text of this section are followed by a level of evidence. The PDQ editorial boards use a formal ranking system to help the reader judge the strength of evidence linked to the reported results of a therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence for more information.)
Incidence and Mortality
Estimated new cases and deaths from colon cancer in the United States in 2011:
New cases: 101,340 (colon cancer only).
Deaths: 49,380 (colon...
This web site, developed by the nonprofit Coalition of Cancer Cooperative Groups, is an unbiased cancer clinical trial matching and navigation service enabling patients to search for cancer trials based on disease and location.